866-997-4948(US-Canada Toll Free)

Radiopharmaceutical Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Published By :

Transparency Market Research

Published Date : Oct 2016

Category :

Pharmaceutical

No. of Pages : 246 Pages

Radiopharmaceutical Market: Scope and Trends

This report on the radiopharmaceutical market analyzes the current and future scenario of the global market. Increase in incidence of various diseases, development of new sources for radioisotope production, and rise in demand for nuclear medicine are boosting the radiopharmaceutical market. Increase in incidence of cancer and cardiovascular diseases, growth in awareness about effective use of radiopharmaceuticals, and rise in preference for SPECT and PET scans are some of the factors expected to drive the growth of the global radiopharmaceutical market during the forecast period.

The radiopharmaceutical market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the global market with respect to the segments based on radioisotopes, source, end-user, and geography. A detailed qualitative analysis of drivers and restraints, and opportunities has been provided in the market overview section. Additionally, the section comprises Porters Five Forces Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global radiopharmaceutical market.

Radiopharmaceutical Market: Segmentation

Based on radioisotope, the market has been segmented into Technetium-99, Lutetium-177, Rubidium-87, Iodine-123, Yttrium-90, and Gallium-62. Technetium-99 is the most widely used radioisotope across the globe; around 70% of radiopharmaceutical companies depend on Mo-99 to produce Technetium-99, as per the World Nuclear Association. The market segments have been analyzed based on available approved products, cost-effectiveness, and preference for technological systems by physicians and patients. The market size and forecast for each of these segments have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2016 to 2024, considering 2015 as the base year.

Based on source, the radiopharmaceutical market has been segmented into two major categories: nuclear reactors and cyclotrons. The market segments have been extensively analyzed based on increase in demand for radioisotopes for nuclear medicines, availability of radioisotopes and raw materials, radioisotopes short half-life and number of production units used for production of radioisotopes. Different types of end-user utilize radiopharmaceutical products to treat diseases either through imaging techniques or the therapeutics method.

Under the end-user segment, hospitals plays a major role followed by ambulatory surgical centers, diagnostic centers, and others (such as universities, research laboratories, and pathology labs). The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2014 to 2024. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2016 to 2024, considering 2015 as the base year. Application segment signifies the usage of radiopharmaceutical products through different disease indication such as oncology, cardiology, neurology, nephrology, gastroenterology, immunology and others. Oncology segment is the dominant sector which emphasizes the use of different radioisotopes for treating various cancers and overcome the side effects of therapeutics. Brachytherapy is a sub segment of oncology application which signifies the methods of treating cancer through implants, surgery or radiation technology. The segment is expected to have a significant growth during the forecast period. 

Geographically, the global radiopharmaceutical market has been categorized into five major regions and the key countries in the respective region: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, Japan, China, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, Saudi Arabia, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2016 to 2024, considering 2015 as the base year.

Radiopharmaceutical Market: Competitive Landscape

The report also profiles major players in the global radiopharmaceutical market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Advanced Accelerator Applications (AAA), Eckert & Ziegler, GE Healthcare, IBA Radiopharma Solutions, Lantheus Holdings, Inc., Mallinckrodt plc., Nordion, Inc., Siemens Healthineers, and Positron Corporation.

The global radiopharmaceutical market has been segmented as follows:

Global Radiopharmaceutical Market, by Radioisotope

  • Technetium-99
  • Gallium-67
  • Iodine-123
  • 18F
  • Rubidium-82
  • Yttrium-90
  • Lutetium-177

Global Radiopharmaceutical Market, by Source

  • Nuclear Reactors
  • Cyclotrons

Global Radiopharmaceutical Market, by End-user

  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Centers
  • Others

Global Radiopharmaceutical Market, by Application

  • Cardiology
  • Gastroenterology
  • Oncology
  • Brachytherapy
  • Others
  • Nephrology
  • Neurology
  • Immunology
  • Others

Global Radiopharmaceutical Market, by Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • Japan
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Radiopharmaceutical Market

4. Market Overview
4.1. Introduction
4.1.1. Radioisotopes Definition
4.1.2. Industry Evolution / Developments
4.2.Overview
4.3. Key Market Indicators
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.5. Global Radiopharmaceutical Market Analysis and Forecasts, 2014–2024
4.5.1. Market Revenue Projections (US$ Mn)
4.7. Porter’s Five Force Analysis
4.8. Value Chain Analysis
4.9. Market Outlook
4.9.1. FDA Approved Radiopharmaceutical Products, By Manufacturers & Trade Name 
4.9.2. Market Size (US$ Mn) & Forecast, 2014-2024
4.9.3. Market Share (%), By Segments, 2016
4.9.4. Global Supply Demand Scenario, By Country, 2015
4.10. Application of Radiopharmaceutical (Peptide Receptor Radionuclide Therapy (PRRT) and Brachytherapy

5. Global Radiopharmaceutical Market Analysis and Forecasts, By Radioisotopes 
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value Analysis Forecast By Radioisotopes , 2014–2024
5.4.1. Technetium-99
5.4.2. Gallium-67
5.4.3. Iodine-123
5.4.4. Iodine-125
5.4.5. 18F
5.4.6. Rubidium-82
5.4.7. Yttrium-90
5.4.8. Lutetium-177
5.4.9. Others
5.5. RadioisotopesComparison Matrix
5.6. Market Attractiveness By Radioisotopes 

6. Global Radiopharmaceutical Market Analysis and Forecasts, By Source 
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Value Analysis Forecast By Source , 2014–2024
6.4.1. Nuclear Reactors
6.4.2. Cyclotrons
6.5. SourceComparison Matrix
6.6. Market Attractiveness By Source 

7. Global Radiopharmaceutical Market Analysis and Forecasts, By End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Key Trends
7.4. Market Value Analysis Forecast By Application, 2014–2024
7.4.1. Cardiology
7.4.2. Gastroenterology
7.4.3. Oncology
 7.4.3.1. Brachytherapy
 7.4.3.2. Others
7.4.4. Nephrology
7.4.5. Neurology
7.4.6. Immunology
7.4.7. Others
7.5. End-user Comparison Matrix
7.6. Market Attractiveness By End-user

8. Global Radiopharmaceutical Market Analysis and Forecasts, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Key Trends
8.4. Market Value Analysis Forecast By End-user, 2014–2024
8.4.1. Hospitals
8.4.2. Ambulatory Surgical Centers
8.4.3. Diagnostic Centers
8.4.4. Cancer Research Institutes
8.4.5. Others
8.5. End-user Comparison Matrix
8.6. Market Attractiveness By End-user

9. Global Radiopharmaceutical Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Policies and Regulations
9.3. Market Value Analysis Forecast By Region
9.3.1. North America 
9.3.2. Europe 
9.3.3. Asia Pacific 
9.3.4. Latin America 
9.3.5. Middle East and Africa 
9.4. Market Attractiveness By Country/Region

10. North America Radiopharmaceutical Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Policies and Regulations
10.2. Market Value Analysis Forecast By Radioisotopes , 2014–2024
10.2.1. Technetium-99
10.2.2. Gallium-67
10.2.3. Iodine-123
10.2.4. Iodine-125
10.2.5. 18F
10.2.6. Rubidium-82
10.2.7. Yttrium-90
10.2.8. Lutetium-177
10.2.9. Others
10.3. Market Value Analysis Forecast By Source , 2014–2024
10.3.1. Nuclear Reactors
10.3.2. Cyclotrons
10.4. Market Value Analysis Forecast By Application, 2014–2024
10.4.1. Cardiology
10.4.2. Gastroenterology
10.4.3. Oncology
 10.4.3.1. Brachytherapy
 10.4.3.2. Others
10.4.4. Nephrology
10.4.5. Neurology
10.4.6. Immunology
10.4.7. Others
10.5. Market Value Analysis Forecast By End-user, 2014–2024
10.5.1. Hospitals
10.5.2. Ambulatory Surgical Centers
10.5.3. Diagnostic Centers
10.5.4. Cancer Research Institutes
10.5.5. Others
10.6. Market Value Analysis Forecast By Country , 2014–2024
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis 
10.7.1. By Radioisotopes 
10.7.2. By Source 
10.7.3. By End-user
10.7.4. By End-user
10.7.5. By Country

11. Europe Radiopharmaceutical Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Policies and Regulations
11.2. Market Value Analysis Forecast By Radioisotopes , 2014–2024
11.2.1. Technetium-99
11.2.2. Gallium-67
11.2.3. Iodine-123
11.2.4. Iodine-125
11.2.5. 18F
11.2.6. Rubidium-82
11.2.7. Yttrium-90
11.2.8. Lutetium-177
11.2.9. Others
11.3. Market Value Analysis Forecast By Source , 2014–2024
11.3.1. Nuclear Reactors
11.3.2. Cyclotrons
11.4. Market Value Analysis Forecast By Application, 2014–2024
11.4.1. Cardiology
11.4.2. Gastroenterology
11.4.3. Oncology
 11.4.3.1. Brachytherapy
 11.4.3.2. Others
11.4.4. Nephrology
11.4.5. Neurology
11.4.6. Immunology
11.4.7. Others
11.5. Market Value Analysis Forecast By End-user, 2014–2024
11.5.1. Hospitals
11.5.2. Ambulatory Surgical Centers
11.5.3. Diagnostic Centers
11.5.4. Cancer Research Institutes
11.5.5. Others
11.6. Market Value Analysis Forecast By Country , 2014–2024
11.6.1. U.K.
11.6.2. Germany
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis 
11.7.1. By Radioisotopes 
11.7.2. By Source 
11.7.3. By End-user
11.7.4. By End-user
11.7.5. By Country

12. Asia Pacific Radiopharmaceutical Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.1.2. Policies and Regulations
12.2. Market Value Analysis Forecast By Radioisotopes , 2014–2024
12.2.1. Technetium-99
12.2.2. Gallium-67
12.2.3. Iodine-123
12.2.4. Iodine-125
12.2.5. 18F
12.2.6. Rubidium-82
12.2.7. Yttrium-90
12.2.8. Lutetium-177
12.2.9. Others
12.3. Market Value Analysis Forecast By Source , 2014–2024
12.3.1. Nuclear Reactors
12.3.2. Cyclotrons
12.4. Market Value Analysis Forecast By Application , 2014–2024
12.4.1. Cardiology
12.4.2. Gastroenterology
12.4.3. Oncology
 12.4.3.1. Brachytherapy
 12.4.3.2. Others
12.4.4. Nephrology
12.4.5. Neurology
12.4.6. Immunology
12.4.7. Others
12.5. Market Value Analysis Forecast By End-user, 2014–2024
12.5.1. Hospitals
12.5.2. Ambulatory Surgical Centers
12.5.3. Diagnostic Centers
12.5.4. Cancer Research Institutes
12.5.5. Others
12.6. Market Value Analysis Forecast By Country , 2014–2024
12.6.1. India
12.6.2. China
12.6.3. Japan
12.6.4. Australia
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis 
12.7.1. By Radioisotopes 
12.7.2. By Source 
12.7.3. By End-user
12.7.4. By End-user
12.7.5. By Country

13. Latin America Radiopharmaceutical Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.1.2. Policies and Regulations
13.2. Market Value Analysis Forecast By Radioisotopes , 2014–2024
13.2.1. Technetium-99
13.2.2. Gallium-67
13.2.3. Iodine-123
13.2.4. Iodine-125
13.2.5. 18F
13.2.6. Rubidium-82
13.2.7. Yttrium-90
13.2.8. Lutetium-177
13.2.9. Others
13.3. Market Value Analysis Forecast By Source , 2014–2024
13.3.1. Nuclear Reactors
13.3.2. Cyclotrons
13.4. Market Value Analysis Forecast By Application, 2014–2024
13.4.1. Cardiology
13.4.2. Gastroenterology
13.4.3. Oncology
13.4.3.1. Brachytherapy
13.4.3.2. Others
13.4.4. Nephrology
13.4.5. Neurology
13.4.6. Immunology
13.4.7. Others
13.5. Market Value Analysis Forecast By End-user, 2014–2024
13.5.1. Hospitals
13.5.2. Ambulatory Surgical Centers
13.5.3. Diagnostic Centers
13.5.4. Cancer Research Institutes
13.5.5. Others
13.6. Market Value Analysis Forecast By Country , 2014–2024
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis 
13.7.1. By Radioisotopes 
13.7.2. By Source 
13.7.3. By End-user
13.7.4. By End-user
13.7.5. By Country

14. Middle East and Africa Radiopharmaceutical Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.1.2. Policies and Regulations
14.2. Market Value Analysis Forecast By Radioisotopes , 2014–2024
14.2.1. Technetium-99
14.2.2. Gallium-67
14.2.3. Iodine-123
14.2.4. Iodine-125
14.2.5. 18F
14.2.6. Rubidium-82
14.2.7. Yttrium-90
14.2.8. Lutetium-177
14.2.9. Others
14.3. Market Value Analysis Forecast By Source , 2014–2024
14.3.1. Nuclear Reactors
14.3.2. Cyclotrons
14.4. Market Value Analysis Forecast By Application, 2014–2024
14.4.1. Cardiology
14.4.2. Gastroenterology
14.4.3. Oncology
14.4.3.1. Brachytherapy
14.4.3.2. Others
14.4.4. Nephrology
14.4.5. Neurology
14.4.6. Immunology
14.4.7. Others
14.5. Market Value Analysis Forecast By End-user, 2014–2024
14.5.1. Hospitals
14.5.2. Ambulatory Surgical Centers
14.5.3. Diagnostic Centers
14.5.4. Cancer Research Institutes
14.5.5. Others
14.6. Market Value Analysis Forecast By Country , 2014–2024
14.6.1. South Africa
14.6.2. Saudi Arabia
14.6.3. Rest of Middle East and Africa
14.7. Market Attractiveness Analysis 
14.7.1. By Radioisotopes 
14.7.2. By Source 
14.7.3. By End-user
14.7.4. By End-user
14.7.5. By Country

15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2015)
15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
15.3.1. Advanced Accelerator Applications (AAA)
15.3.1.1. Overview
15.3.1.2. Financials
15.3.1.3. Recent Developments
15.3.1.4. Strategy
15.3.2. Bayer AG
15.3.2.1. Overview
15.3.2.2. Financials
15.3.2.3. Recent Developments
15.3.2.4. Strategy
15.3.3. Eckert & Ziegler 
15.3.3.1. Overview
15.3.3.2. Financials
15.3.3.3. Recent Developments
15.3.3.4. Strategy
15.3.4. GE Healthcare 
15.3.4.1. Overview
15.3.4.2. Financials
15.3.4.3. Recent Developments
15.3.4.4. Strategy
15.3.5. IBA Radiopharma Solutions 
15.3.5.1. Overview
15.3.5.2. Financials
15.3.5.3. Recent Developments
15.3.5.4. Strategy
15.3.6. Lantheus Holdings, Inc. 
15.3.6.1. Overview
15.3.6.2. Financials
15.3.6.3. Recent Developments
15.3.6.4. Strategy
15.3.7. Mallinckrodt plc. 
15.3.7.1. Overview
15.3.7.2. Financials
15.3.7.3. Recent Developments
15.3.7.4. Strategy
15.3.8. Nordion, Inc. 
15.3.8.1. Overview
15.3.8.2. Financials
15.3.8.3. Recent Developments
15.3.8.4. Strategy
15.3.9. Positron Corporation 
15.3.9.1. Overview
15.3.9.2. Financials
15.3.9.3. Recent Developments
15.3.9.4. Strategy
15.3.10. Siemens Healthineers
15.3.10.1. Overview
15.3.10.2. Financials
15.3.10.3. Recent Developments
15.3.10.4. Strategy

List of Table

Table 1: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014–2024
Table 2: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 3: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 4: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by Oncology Application, 2014–2024
Table 5: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 6: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 7: North America Radiopharmaceutical Market Size (US$ Mn) Forecast, By Country, 2014–2024
Table 8: North America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014–2024
Table 9: North America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 10: North America Radiopharmaceuticals Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 11: North America Radiopharmaceuticals Market Size (US$ Mn) Forecast, by Oncology Application, 2014–2024
Table 12: North America Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 13: Europe Radiopharmaceutical Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 14: Europe Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014–2024
Table 15: Europe Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 16: Europe Radiopharmaceuticals Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 17: Europe Radiopharmaceuticals Market Size (US$ Mn) Forecast, by Oncology Application, 2014–2024
Table 18: Europe Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 19: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 20: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014–2024
Table 21: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 22: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 23: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Oncology Application, 2014–2024
Table 24: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 25: Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 26: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014–2024
Table 27: Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 28: Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 29: Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Oncology Application, 2014–2024
Table 30: Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 31: Middle East & Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 32: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014–2024
Table 33: Middle East & Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 34: Middle East and Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 35: Middle East and Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, by Oncology Application, 2014–2024
Table 36: Middle East & Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014–2024

List of Chart

FIG. 1 Global Radiopharmaceutical Market Size (US$ Mn) Forecast, 2014–2024
FIG. 3 Market Value Share, by Source (2016)
FIG. 5 Market Value Share, by End-user (2016)
FIG. 2 Market Value Share, by Radioisotope (2016)
FIG. 4 Market Value Share, by Application (2016)
FIG. 6 Global Radiopharmaceutical Market Value Share Analysis, by Radioisotope, 2016 and 2024
FIG. 7 Global Technetium-99 Market Revenue 
FIG. 8 Global Gallium-67 Market Revenue 
FIG. 9 Global Iodine-123 Market Revenue 
FIG. 10 Global 18F Market Revenue (US$ Mn), 
FIG. 11 Global Rubidium-82 Market Revenue 
FIG. 12 Global Yttrium-90 Market Revenue (US$ Mn), 2014–2024
FIG. 13 Global Lutetium-177 Market Revenue 
FIG. 14 Global Iodine-125 Market Revenue (US$ Mn), 2014–2024
FIG. 15 Global Other Radioisotope Market Revenue (US$ Mn), 2014–2024
FIG. 16 Global Radiopharmaceutical Market Attractiveness Analysis, by Radioisotope, 2016-2024
FIG. 17 Global Radiopharmaceutical Market Value Share Analysis, by Source, 2016 and 2024
FIG. 18 Global Nuclear Reactor Market Revenue 
FIG. 19 Global Cyclotrons Market Revenue (US$ Mn), 2014–2024
FIG. 20 Global Radiopharmaceutical Market Attractiveness Analysis, by Source 2016 and 2024
FIG. 21 Global Radiopharmaceutical Market Value Share Analysis, by Application, 2016 and 2024
FIG. 22 Global Radiopharmaceutical Market Value Share Analysis, by Oncology Application, 2016 and 2024
FIG. 23 Global Cardiology Market Revenue 
FIG. 24 Global Gastroenterology Market Revenue 
FIG. 25 Global Oncology Market Revenue 
FIG. 26 Global Nephrology Market Revenue (US$ Mn), 
FIG. 27 Global Neurology Market Revenue 
FIG. 28 Global Immunology Market Revenue (US$ Mn), 2014–2024
FIG. 29 Global Others Market Revenue (US$ Mn), 2014–2024
FIG. 30 Global Brachytherapy Market Revenue 
FIG. 31 Global Others Market Revenue (US$ Mn), 2014–2024
FIG. 32 Global Radiopharmaceutical Market Attractiveness Analysis, by Application, 2016-2024
FIG. 33 Global Radiopharmaceutical Market Value Share Analysis, by End-user, 2016 and 2024
FIG. 34 Global Hospitals Market Revenue (US$ Mn), 2014–2024
FIG. 35 Global Ambulatory Surgical Center Market Revenue (US$ Mn), 2014–2024
FIG. 36 Global Diagnostic Centers Market Revenue 
FIG. 37 Global Others Market Revenue (US$ Mn), 
FIG. 38 Global Other End user Market Revenue 
FIG. 39 Global Radiopharmaceutical Market Attractiveness Analysis, by End-user, 2016-2024
FIG. 40 Global Radiopharmaceutical Market Value Share Analysis, by Region, 2016 and 2024
FIG. 41 Global Radiopharmaceutical Market Attractiveness Analysis, by Region, 2016-2024
FIG. 42 North America Radiopharmaceutical Market Size
FIG. 43 North America Market Attractiveness Analysis,
FIG. 44 North America Market Value Share Analysis By Country, 2016 and 2024
FIG. 45 North America Market Value Share Analysis Source, 2016 and 2024
FIG. 46 North America Market Value Share Analysis by Source, 2016 and 2024
FIG. 47 North America Radiopharmaceuticals Market Value Share Analysis, by Application, 2016 and 2024
FIG. 48 North America Radiopharmaceuticals Market Value Share Analysis, by Oncology Application, 2016 and 2024
FIG. 49 North America Market Value Share Analysis by End-user, 2016 and 2024
FIG. 50 North America Market Attractiveness Analysis by Radioisotope, 2016-2024
FIG. 51 North America Market Attractiveness Analysis by Source, 2016-2024
FIG. 52 North America Market Attractiveness Analysis by Application, 2016-2024
FIG. 53 North America Market Attractiveness Analysis by End –user, 2016-2024
FIG. 54 Europe Radiopharmaceutical Market Size (US$ Mn) Forecast, 2014–2024
FIG. 55 Europe Market Attractiveness Analysis, by Country, 2016–2024
FIG. 56 Europe Market Value Share Analysis, by Country, 2016 and 2024
FIG. 57 Europe Market Value Share Analysis, by Radioisotope, 2016 and 2024
FIG. 58 Europe Market Value Share Analysis, by Source, 2016 and 2024
FIG. 59 Europe Radiopharmaceuticals Market Value Share Analysis, by Application, 2016 and 2024
FIG. 60 Europe Radiopharmaceuticals Market Value Share Analysis, by Oncology Application, 2016 and 2024
FIG. 61 Europe Market Value Share Analysis, by End-user, 2016 and 2024
FIG. 62 North America Market Attractiveness Analysis by Radioisotope, 2016-2024
FIG. 63 North America Market Attractiveness Analysis by Source, 2016-2024
FIG. 64 North America Market Attractiveness Analysis by Application, 2016-2024
FIG. 65 North America Market Attractiveness Analysis by End –user, 2016-2024
FIG. 66 Asia Pacific Radiopharmaceutical Market Size
FIG. 67 Asia Pacific Radiopharmaceutical Market Attractiveness Analysis, by Country, 2016–2024
FIG. 68 Asia Pacific Radiopharmaceutical Market Value Share Analysis, by Country, 2016 and 2024
FIG. 69 Asia Pacific Radiopharmaceutical Market Value Share Analysis, by Radioisotope, 2016 and 2024
FIG. 70 Asia Pacific Radiopharmaceutical Market Value Share Analysis, by Source, 2016 and 2024
FIG. 71 Asia Pacific Market Value Share Analysis, by Application, 2016 and 2024
FIG. 72 Asia Pacific Market Value Share Analysis, by Oncology Application, 2016 and 2024
FIG. 73 Asia Pacific Radiopharmaceutical Market Value Share Analysis, by End-user, 2016 and 2024
FIG. 74 Asia Pacific Market Attractiveness Analysis by Radioisotope, 2016-2024
FIG. 75 Asia Pacific Market Attractiveness Analysis by Source, 2016-2024
FIG. 76 Asia Pacific Market Attractiveness Analysis by Application, 2016-2024
FIG. 77 Asia Pacific Market Attractiveness Analysis by End –user, 2016-2024
FIG. 78 Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, 2014–2024
FIG. 79 Latin America Market Attractiveness Analysis, by Country, 2016–2024
FIG. 80 Latin America Radiopharmaceutical Market Value Share Analysis, by Country, 2016 and 2024
FIG. 81 Latin America Market Value Share Analysis, by Radioisotope, 2016 and 2024
FIG. 82 Latin America Market Value Share Analysis, by Source, 2016 and 2024
FIG. 83 Latin America Market Value Share Analysis, by Application, 2016 and 2024
FIG. 84 Latin America Market Value Share Analysis, by Oncology Application, 2016 and 2024
FIG. 85 Latin America Market Value Share Analysis, by End-user, 2016 and 2024
FIG. 86 Latin America Market Attractiveness Analysis by Radioisotope, 2016-2024
FIG. 87 Latin America Market Attractiveness Analysis by Source, 2016-2024
FIG. 88 Latin America Market Attractiveness Analysis by Application, 2016-2024
FIG. 89 Latin America Market Attractiveness Analysis by End –user, 2016-2024
FIG. 90 Middle East & Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, 2014–2024
FIG. 91 Middle East & Africa Radiopharmaceutical Market Attractiveness Analysis, by Country, 2016–2024
FIG. 92 Middle East & Africa Radiopharmaceutical Market Value Share Analysis, by Country, 2016 and 2024
FIG. 93 Middle East & Africa Radiopharmaceutical Market Value Share Analysis, by Radioisotope, 2016 and 2024
FIG. 94 Middle East & Africa Market Value Share Analysis,
FIG. 95 Middle East and Africa Market Value Share Analysis, by Application, 2016 and 2024
FIG. 96 Middle East and Africa Market Value Share Analysis, by Oncology Application, 2016 and 2024
FIG. 97 Middle East & Africa Radiopharmaceutical Market Value Share Analysis, by End-user, 2016 and 2024
FIG. 98 Middle East and Africa Market Attractiveness Analysis by Radioisotope, 2016-2024
FIG. 99 Middle East and Africa Market Attractiveness Analysis by Source, 2016-2024
FIG. 100 Middle East and Africa Market Attractiveness Analysis by Application, 2016-2024
FIG. 101 Middle East and Africa Market Attractiveness Analysis by End –user, 2016-2024
FIG. 102 Global Radiopharmaceutical Market Share Analysis, by Company (2015)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *